TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32603389
Drug: CO2 laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 laser ablative fractional resurfacing (AFR) followed by ALA photodynamic therapy (PDT)
Study: 32603389
Drug: ALA photodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA photodynamic therapy (PDT) alone
Study: 34718434
Drug: Tocilizumab weekly
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab weekly (TCZ QW)
Study: 32393496
Drug: 3,600 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3,600 mg MHAA4549A + OTV
Study: 32393496
Drug: 8,400 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8,400 mg MHAA4549A + OTV
Study: 35688490
Drug: Micronised progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronised progesterone (Utrogestan® 200mg) + transdermal oestradiol (Evorel® Patches 50mcg/day)
Study: 35688490
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (Provera® 10mg) + transdermal oestradiol (Evorel® Patches 50mcg/day)
Study: 33472681
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma (single infusion) plus standard of care (SOC)
Study: 32125903
Drug: Methylphenidate hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate hydrochloride extended-release capsules (MPH-MLR) 10 mg once daily, with weekly adjustments up to 40 mg.
Study: 32125903
Drug: Methylphenidate hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate hydrochloride extended-release capsules (MPH-MLR)
Study: 32507386
Drug: Single-infusion donor-derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-infusion donor-derived anti-CD19 CAR T cells
Study: 35287091
Drug: Droperidol 5
Normalized name: droPERidol 5 MG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 5 mg/midazolam 5 mg IM
Study: 35287091
Drug: Haloperidol 5
Normalized name: haloperidol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 5 mg/lorazepam 2 mg IM
Study: 35939501
Drug: UV-4 hydrochloride
Normalized name: adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: UV-4 hydrochloride (UV-4B) at doses of 3, 10, 30, 90, 180, 360, 720, or 1000 mg
Study: 33148955
Drug: 1-g intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-g intravenous (IV) TXA prior to incision (single-dose IV group)
Study: 33148955
Drug: 1-g IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-g IV TXA prior to incision followed by 1-g IV TXA after arthrotomy wound closure (double-dose IV group)
Study: 33148955
Drug: 1-g IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-g IV TXA prior to incision and 1-g intraoperative topical TXA (combined IV and topical group)
Study: 33148955
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses totaling 1,950-mg oral TXA (multidose oral group)
Study: 35120150
Drug: Formula supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula supplementation (up to 59 milliliters administered daily for 30 days)
Study: 35564709
Drug: Blueberry juice
Normalized name: lowbush blueberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blueberry juice (60 mL per day for 20 days)
Study: 35564709
Drug: Placebo (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (60 mL per day for 20 days)
Study: 33803802
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of oat oil with a high concentration (40%) of polar lipids (PLH)
Study: 33803802
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of rapeseed oil (RSO)
Study: 33803802
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of oat oil with a low concentration (4%) of polar lipids (PLL)
Study: 33099836
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of FCO2 and FRF
Study: 32882447
Drug: Monthly aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monthly aflibercept injections (2 mg)
Study: 32882447
Drug: Quarterly aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Quarterly aflibercept injections (2 mg)
Study: 32882447
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (monthly and quarterly aflibercept injections)
Study: 36107843
Drug: OC‐01 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC‐01 0.03 mg BID
Study: 36107843
Drug: OC‐01 0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC‐01 0.06 mg BID
Study: 36107843
Drug: Vehicle nasal
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle nasal spray BID
Study: 39429046
Drug: Dietetic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietetic treatment
Study: 34635804
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT) treatment once a week for four weeks with 3000 impulses each
Study: 34635804
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with air-filled microspheres
Study: 35387483
Drug: Ticagrelor 60
Normalized name: ticagrelor 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 60 mg BD
Study: 35387483
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg OD
Study: 32879783
Drug: Levosulpiride (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosulpiride (25 mg orally TID for 7 days)
Study: 32879783
Drug: Placebo (lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose pill, orally TID for 7 days)
Study: 35093013
Drug: Atogepant 30
Normalized name: atogepant 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atogepant 30 mg
Study: 32512353
Drug: Adjunctive group-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive group-based psychosocial intervention (12 weekly sessions and 3 monthly booster sessions)
Study: 32970235
Drug: Other exposure
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other exposure status (less nutritious supplement or improved nutrition at other ages)
Study: 36384493
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy combined with NBP treatment (NBP 200 mg, three times per day for 24 weeks)
Study: 33746857
Drug: Modular Approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modular Approach to Therapy for Children (MATCH)
Study: 35199250
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green injection with the da Vinci Xi‐equipped Firefly system
Study: 35123236
Drug: Push-pull with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Push-pull with 60 mL syringe
Study: 35123236
Drug: Push-pull with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Push-pull with 10 mL syringe
Study: 36052536
Drug: Enfortumab vedotin
Normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enfortumab vedotin (EV) 1.25 mg/kg on Days 1, 8, and 15 for 28-day cycles
Study: 36052536
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (SC; docetaxel or paclitaxel) on Day 1 of each 21-day cycle
Study: 34688923
Drug: Present-centered group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Present-centered group therapy (control)
Study: 96008295
Drug: Interferon-alpha (IFN-alpha)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha (IFN-alpha) at a dose of 5MU daily or 10 MU three times a week for 3 to 6 months
Study: 96008295
Drug: Combination therapies
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapies including interferon alpha with Ara-AMP, acyclovir, didoxynucleoside or interferon-gamma
Study: 35715644
Drug: Astodrimer sodium
Normalized name: Astodrimer
DrugBank: Astodrimer (DB11854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astodrimer sodium nasal spray (1%)
Study: 33426570
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid gel (HAG)
Study: 34352588
Drug: EP prenylflavonoid
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP prenylflavonoid extract (740 mg daily)
Study: 36379585
Drug: Add-on imeglimin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on imeglimin 1000 mg two times per day
Study: 36379585
Drug: Metformin dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin dose escalation
Study: 33300818
Drug: Montelukast formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast formulations
Study: 32167260
Drug: Ganglion cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganglion cell complex thickness-to-total retinal thickness ratio (G/T ratio)
Study: 32123969
Drug: octreotide LAR
Normalized name: octreotide LAR 20 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: octreotide LAR 60 mg
Study: 35698187
Drug: Myofascial Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofascial Release Therapy
Study: 35057905
Drug: Intravaginal lactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal lactic acid gel (5 ml once daily for 7 days)
Study: 35057905
Drug: Oral metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metronidazole (400 mg twice daily for 7 days)
Study: 33434727
Drug: Mindfulness-based group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based group therapy (MBGT) + Treatment-as-usual (TAU)
Study: 36384950
Drug: Community-based education
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based education and peer support programme led by women's self-help group members; assistance in daily hypertension management, social and emotional support, referral to primary healthcare system.
Study: 32315289
Drug: Intragastric infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intragastric infusion of glucose
Study: 32315289
Drug: Intragastric infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intragastric infusion of water
Study: 32315289
Drug: Baseline levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline levels of peripheral appetite hormones
Study: 34049538
Drug: Traditional one-year
Normalized name: segesterone
DrugBank: Segesterone (DB14584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional one-year family medicine residency program
Study: 35380374
Drug: ON-SXB 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ON-SXB 7.5 g
Study: 36216727
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg of remifentanil dissolved in 25 ml of saline
Study: 36216727
Drug: 25 ml
Normalized name: ethanol 6.025 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 ml of intra‐articular normal saline
Study: 36316939
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine-based rehabilitation nursing combined with scalp acupuncture (TCMRN + SA)
Study: 36316939
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine-based rehabilitation nursing (TCMRN)
Study: 35677618
Drug: Siddha medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siddha medicine preparation (Nochi Kudineer Chooranam 5 gm, Mahasudarsan Chooranam 3 gm, Adathodai Manapagu 10 ml, Omatheeneer 10 ml, Maldevi chenduram 100 mg with honey) for 7 days
Study: 34653721
Drug: Local Anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local Anesthetic Injection (LAI)
Study: 34653721
Drug: Intraperitoneal Local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal Local Anesthetic Injection (IPLA)
Study: 34862871
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no targeted drug)
Study: 35313949
Drug: treatment-as-usual +
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment-as-usual + AppBM
Study: 35313949
Drug: treatment-as-usual +
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment-as-usual + Sham
Study: 35313949
Drug: treatment-as-usual only
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment-as-usual only
Study: 35277340
Drug: Lidocaine plus
Normalized name: Icy Hot Lidocaine Plus Menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine plus paracetamol
Study: 35277340
Drug: Lidocaine plus
Normalized name: Icy Hot Lidocaine Plus Menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine plus morphine (control)
Study: 33087171
Drug: Opioid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid treatment
Study: 32835826
Drug: Alternative analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative analgesic agents
Study: 32453396
Drug: DHA (465
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (465 mg) plus vitamin E (600 IU)
Study: 32453396
Drug: DHA (465
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (465 mg) plus placebo
Study: 32453396
Drug: Both placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both placebo capsules
Study: 32249311
Drug: Thiopental infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental infusion
Study: 35603411
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (BRJ) 70 mL (400 mg of nitrate)
Study: 32295483
Drug: Cognitive training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive training (CT) programme for 12 weeks, 45 min twice a week
Study: 32621465
Drug: Navigational dual-target
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navigational dual-target high-frequency rTMS (10 Hz) applied over the primary motor cortex (M1) and left dorsolateral prefrontal cortex (DLPFC) for 20 daily sessions over 3 weeks.
Study: 32621465
Drug: Placebo rTMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo rTMS (10 Hz) applied over the same areas for 20 daily sessions over 3 weeks.
Study: 32937023
Drug: telmisartan/amlodipine 80/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: telmisartan/amlodipine 80/5 mg + rosuvastatin 20 mg
Study: 32937023
Drug: telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: telmisartan 80 mg + rosuvastatin 20 mg
Study: 32937023
Drug: telmisartan/amlodipine 80/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: telmisartan/amlodipine 80/5 mg
Study: 33721444
Drug: Cetuximab combined
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab combined with IMRT and concurrent cisplatin‐based chemotherapy
Study: 33721444
Drug: IMRT combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMRT combined with concurrent cisplatin‐based chemotherapy (Control group)
Study: 35750460
Drug: Fosfomycin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfomycin (3 g single dose) and two placebo tablets three times a day for 7 days
Study: 33938936
Drug: Nivolumab-Ipilimumab combination
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab-Ipilimumab combination therapy
Study: 32366948
Drug: Helicobacter pylori
Normalized name: HELICOBACTER PYLORI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helicobacter pylori (Hp) sero-positivity with periodontal pathogens (e.g., Prevotella intermedia, Campylobacter Rectus, Actinomyces Naeslundii)
Study: 32612574
Drug: Combined Oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Oral Contraceptive (COC)
Study: 34610254
Drug: Timolol 0.5%
Normalized name: Timolol 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.5% dosed twice daily
Study: 36173041
Drug: Gluten-containing diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gluten-containing diet (14 g/day gluten for 14 days)
Study: 33150745
Drug: GnRHAG (gonadotropin‐releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRHAG (gonadotropin‐releasing hormone agonist) for 24 weeks (n = 14)
Study: 35078574
Drug: Leptin (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leptin (50, 100, 200, 400 ng/mL)
Study: 35078574
Drug: Leptin (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leptin (after knockdown of MMP14 and leptin receptor genes)
Study: 35078574
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no leptin treatment)
Study: 34939265
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ARS and Traditional Lecture
Study: 33123587
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (oral Chinese and western medicine)
Study: 35757326
Drug: G‐CSF (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (10 mcg/kg/day subcutaneously)
Study: 35757326
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 mL of 0.9% saline subcutaneously)
Study: 36287306
Drug: Berdazimer gel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berdazimer gel, 10.3%
Study: 32238014
Drug: Isotretinoin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin (20 mg/d) plus topical treatments (clobetasol 0.05% and tacrolimus 0.1%)
Study: 32238014
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with topical treatments (clobetasol 0.05% and tacrolimus 0.1%)
Study: 32737891
Drug: Self-report of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-report of very poor/poor oral health
Study: 32737891
Drug: Self-report of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-report of fair oral health
Study: 37267172
Drug: Video directly
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video directly observed therapy (video DOT) for 12 weeks via a mobile health technology platform
Study: 37267172
Drug: Video directly
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video directly observed therapy (video DOT)
Study: 32250672
Drug: Housing Prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Housing Prescriptions as Health Care (integrating priority placement in affordable housing and provision of services such as case management, financial, and legal services)
Study: 36267872
Drug: Tropifexor 30
Normalized name: Tropifexor
DrugBank: Tropifexor (DB16343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropifexor 30 μg
Study: 36267872
Drug: Tropifexor 60
Normalized name: Tropifexor
DrugBank: Tropifexor (DB16343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropifexor 60 μg
Study: 36267872
Drug: Tropifexor 90
Normalized name: Tropifexor
DrugBank: Tropifexor (DB16343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropifexor 90 μg
Study: 36267872
Drug: Tropifexor 150
Normalized name: Tropifexor
DrugBank: Tropifexor (DB16343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropifexor 150 μg
Study: 36267872
Drug: Tropifexor (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropifexor (all doses)
Study: 36271352
Drug: Subcutaneous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous ketamine (0.5 mg/kg)
Study: 36271352
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine (40-min infusion)
Study: 34487870
Drug: Benralizumab 30
Normalized name: benralizumab 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benralizumab 30 mg every 4 or 8 weeks
Study: 38115002
Drug: PfSPZ Vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfSPZ Vaccine
Study: 38695087
Drug: Subcutaneous implantable
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous implantable cardioverter defibrillator (S-ICD)
Study: 33964910
Drug: remestemcel‐L
Approvals — FDA: no, EMA: no, PMDA: no
Description: remestemcel‐L
Study: 36087586
Drug: 5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg R21/25 μg Matrix‐M
Study: 36087586
Drug: 5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg R21/50 μg Matrix‐M
Study: 36087586
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine (Rabivax‐S rabies vaccine)
Study: 32449213
Drug: Lasmiditan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lasmiditan (50 mg, 100 mg, 200 mg)
Study: 32449213
Drug: Lasmiditan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lasmiditan (100 mg, 200 mg)
Study: 35998947
Drug: Meperidine-Ketorolac combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine-Ketorolac combination (1 mg/kg IV meperidine and 30 mg IV ketorolac)
Study: 35998947
Drug: Meperidine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine alone (1 mg/kg IV meperidine)